Anti-Angiogenic Factor Endostatin in Osteosarcoma
H-S Kim, S-J Lim, Y-K Park. Kyung Hee Medical Center, School of Medicine, Kyung Hee University, Seoul, Korea; East-West Neo Medical Center, School of Medicine, Kyung Hee University, Seoul, Korea
Background: Endostatin (ES) is a potent inhibitor of angiogenesis. The expression of ES has not yet been examined in osteosarcoma (OSA). The aim of this study was to analyze the expression of endostatin (ES) and to determine if there is a correlation between the expression of ES and clinicopathological parameters, patient outcomes and/or VEGF expression in OSA.
Design: We made tissue microarrays from 46 cases of OSA and analyzed the expression of ES by immunohistochemistry. A sample was defined as positive when 35% or more of the tumor cells stained positively throughout the tumor core.
Results: Endostatin was expressed in 26.1% (12/46). The expression of ES was significantly correlated with histological grade (P=.008), stage (P=.042) and distant metastasis (P=.011). In contrast, there was no significant correlation between the expression of ES and age (P=.516), tumor size (P=.214), soft tissue extension (P=.498), Huvos grade (P=.547) and VEGF expression (P=1.000). Difference in ES expression among primary sites (P=.375) or histological subtypes (P=.571) was not significant.
Conclusions: Our results suggest that the expression of ES can be used a prognostic factors in OSA patients.
Category: Bone & Soft Tissue
Tuesday, March 10, 2009 9:30 AM
Poster Session III # 18, Tuesday Morning